• Urine Liquid Biopsy Promises Easy Cancer Detection with miRNA, ML

    Nov 19 | Diagnostics World | A team of researchers from Institute of Science Tokyo, Japan, are using nanowires with machine learning analysis to detect cancer-associated miRNAs in urine. Their research findings were published last month online in Analytical Chemistry. More

  • How to Advance Placental Pathology

    Nov 15 | Diagnostics World | Placental pathology has potential to reveal critical insights into pregnancy complications, yet it remains underutilized in clinical trials. By incorporating placental evaluations into clinical research, doctors could better understand and treat conditions like preeclampsia and preterm birth, which are currently diagnosed based only on clinical signs. More

  • Promising Platform for the Pre-Symptomatic Detection of Parkinson’s Disease

    Nov 13 | Diagnostics World | Researchers in Israel recently showcased a novel platform that can be used in the future for the early diagnosis of Parkinson’s disease (PD) by quantifying the distribution of alpha-synuclein (α-syn) in skin biopsies. A proof-of-concept study in humans, supported in part by the Michael J. Fox Foundation, suggests the single-molecule-level detection method might enable the disease to be detected up to 20 years before the first motor symptoms appear. More

  • Breath-Based Tools Look to Battle Deadly Infectious Diseases

    Nov 12 | Diagnostics World | Recent years have seen progress toward developing tools that are designed to analyze a human breath sample to detect, diagnose, or monitor various health issues. Some of these efforts have focused on combating deadly infectious diseases, with intentions of creating cost-effective, easy-to-use breathalyzers capable of being deployed in rural, remote, and low-resource settings. More

  • Novel DELFI Approach Could Bring Space-Age Leaps in Cancer Detection

    Nov 07 | Diagnostics World | A next-generation liquid biopsy approach combining cell-free DNA (cfDNA) “fragmentome” and protein biomarker analyses could aid in the early detection of ovarian cancer, suggests a recent study by researchers in the U.S., The Netherlands, and Denmark. The DELFI-Pro classifier was found to have a high positive predictive value, a key accuracy metric. More

  • New Diagnostic Tool Helps Identify When Antifibrotic Therapy in Breast Cancer Makes Sense

    Nov 04 | Diagnostics World | A diagnostic test invented at the University of Arizona has demonstrated its potential to predict the likelihood of relapse or recurrence among patients with early-stage breast cancer and their response to antifibrotic therapy. The tool, known as MeCo Score, measures metastatic risk based on the acclimation of cancer cells to the mechanical stiffness of tissue (fibrosis) as computed from RNA sequencing data on tumor samples. More

  • The Case Against LDL and HDL Cholesterol Testing is Building

    Oct 31 | Diagnostics World | In another few years, low-density lipoprotein (LDL) and high-density lipoprotein (HDL) analytes may be “obsolete” because the famously bad and good guys in standard cholesterol tests provide less useful information about heart health than other lipid molecules circulating in the blood. The evidence emerges from a recent study in children and adolescents with overweight or obesity finding a new relationship between lipids and diseases impacting metabolism. More

  • Revvity In Vitro Diagnostic Assay, Novel Blood Pressure Monitor, Partnerships, More

    Oct 30 | Diagnostics World | Revvity launches the in vitro diagnostic EURORealTime APOE assay in European countries that accept the CE mark; Withings Health Solutions announces a first-of-its-kind cellular blood pressure monitor; and more. More

  • Follow the Money: Sepsis Diagnostic Test, Next-Gen Tau Tangle Pathology, More

    Oct 29 | Diagnostics World | Cytovale plans to commercially expand IntelliSep, the company’s sepsis diagnostic test, to more hospital emergency departments and health systems nationwide; C2N Diagnostics will continue to develop their next-generation tests specific to tau tangle pathology; and more. More

  • Owkin, AstraZeneca Plan AI Tool for BRCA Screening

    Oct 25 | Diagnostics World | Owkin and AstraZeneca announced a new partnership this month to develop an AI-powered tool to pre-screen for germline BRCA (gBRCA) mutations in breast cancer directly from digitized pathology slides. As part of Owkin’s ongoing collaboration with Gustave Roussy and The Centre Léon Bérard through PortrAIt, a French consortium to accelerate precision medicine through AI-enabled digital pathology, this tool aims to significantly accelerate and expand access to gBRCA testing that too many patients may not be considered for. More
View more articles

 
DXX-Industry-spotlight

merck


Custom Diagnostic Antibody Development & Manufacturing Services

Overcome Process Challenges by outsourcing your custom antibody production to us. How partnering with an antibody production expert can improve your assay, accelerate launch, and maintain your manufacturing.

Learn more